SCHEMBL6619353

SCHEMBL6619353

COCCn1c(=O)c(-c2ccc(F)cc2)c(-c2ccnc(N[C@@H](C)C(C)(C)O)n2)n1C

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 18/20 0.64
MAPK13 O15264 14/20 0.64
MAPK12 P53778 14/20 0.64
MAPK11 Q15759 14/20 0.64
PRKD3 O94806 1/20 0.40
MAP4K4 O95819 1/20 0.40
FRK P42685 1/20 0.40
MAPK8 P45983 1/20 0.40
MAPK9 P45984 1/20 0.40
CSNK1A1 P48729 1/20 0.40
CSNK1D P48730 1/20 0.40
GSK3A P49840 1/20 0.40
GSK3B P49841 1/20 0.40
CSNK1G2 P78368 1/20 0.40
TAOK1 Q7L7X3 1/20 0.40
MINK1 Q8N4C8 1/20 0.40
PRKD2 Q9BZL6 1/20 0.40
CSNK1G1 Q9HCP0 1/20 0.40
MAP3K20 Q9NYL2 1/20 0.40
MAP4K5 Q9Y4K4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6619347 1.00 MAPK14 (0.64) MAPK14MAPK13MAPK12MAPK11PRKD3
SCHEMBL6666766 0.93 MAPK14 (0.64) MAPK14MAPK13MAPK12MAPK11
SCHEMBL6666759 0.93 MAPK14 (0.64) MAPK14MAPK13MAPK12MAPK11
SCHEMBL6622733 0.90 MAPK14 (0.69) MAPK14MAPK13MAPK12MAPK11
SCHEMBL6621579 0.86 MAPK14 (0.73) MAPK14MAPK13MAPK12MAPK11
SCHEMBL6621576 0.86 MAPK14 (0.73) MAPK14MAPK13MAPK12MAPK11
SCHEMBL6636543 0.85 MAPK14 (0.64) MAPK14MAPK13MAPK12MAPK11PRKD3
SCHEMBL6636545 0.85 MAPK14 (0.64) MAPK14MAPK13MAPK12MAPK11PRKD3
SCHEMBL6619266 0.82 MAPK14 (0.69) MAPK14MAPK13MAPK12MAPK11
SCHEMBL6621625 0.80 MAPK14 (0.74) MAPK14MAPK13MAPK12MAPK11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1485167-A1 1,2-DIHYDROPYRAZOL-3-ONES AS CYTOKINE MEDIATORS The Procter & Gamble Company (US) 2004-12-15 EP claimed
US-6677337-B2 RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, INFLAMMATORY BOWEL DISEASE, CACHEXIA, SEPTIC SHOCK, CARDIOVASCULAR AND RESPIRATORY SYSTEM DISORDERS THE PROCTER & GAMBLE COMPANY 2004-01-13 US claimed
US-20030225082-A1 1,2-dihydropyrazol-3-ones which controls inflammatory cytokines PROCTER & GAMBLE COMPANY, THE 2003-12-04 US claimed
WO-2003080184-A1 1,2-DIHYDROPYRAZOL-3-ONES AS CYTOKINE MEDIATORS THE PROCTER & GAMBLE COMPANY (US) 2003-10-02 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225082-A1 1,2-dihydropyrazol-3-ones which controls inflammatory cytokines IL1B, IL1A, IL1R1 MAPK14 1086/4885MAPK13 1053/4885MAPK12 997/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.